Comparative Pharmacology
Head-to-head clinical analysis: ENSKYCE versus GILDESS FE 1 20.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENSKYCE versus GILDESS FE 1 20.
ENSKYCE vs GILDESS FE 1/20
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ENSKYCE (fospropofol disodium) is a prodrug of propofol. It is hydrolyzed by alkaline phosphatases to release propofol, which acts as a positive allosteric modulator of GABA-A receptors, enhancing chloride conductance and producing sedation and anesthesia.
Combination oral contraceptive: ethinyl estradiol suppresses gonadotropin release; norethindrone induces progestational changes in endometrium and cervical mucus, preventing ovulation and fertilization.
2 g IV every 8 hours over 5 hours on days 1-3 of each 21-day cycle
One tablet orally once daily for 21 days followed by 7 placebo tablets per 28-day cycle.
None Documented
None Documented
12 hours (terminal); allows once-daily dosing in most patients
Ethinyl estradiol: terminal half-life approximately 13 hours (range 10-15 h). Desogestrel: metabolized to etonogestrel; etonogestrel terminal half-life about 28 hours (range 20-40 h). Clinical context: steady-state reached within 7-10 days.
Renal: ~70% unchanged; Biliary/Fecal: ~20% as metabolites
Approximately 60-65% renal (as metabolites), 30-35% fecal (as metabolites and unchanged drug). Ethinyl estradiol and desogestrel metabolites are excreted primarily via urine and feces. Etonogestrel (active metabolite) is excreted mainly via feces (40%) and urine (32%).
Category C
Category C
Oral Contraceptive
Oral Contraceptive